Answers are grounded in this paper and cite their sources.
Drugs that inhibit the renin-angiotensin axis (RAS) have largely recognized renoprotective properties. Third generation dihydropyridine calcium channel blockers like lercanidipine (LER), blocking "L" as well as "T-type" calcium activated channels, reduce intraglomerular pressure and urine protein excretion (UprotV) and also might stabilize renal function in several nephropathies.The main aim of this study was to compare the renoprotective efficacy of the addition of losartan (LOS) or LER to patients (Ps) with chronic kidney disease (CKD) receiving monotherapy with enalapril (ENL).
No takes yet. Share an insight, caveat, or question.
Serventi et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: